Philanthropy is the heartbeat of innovation at Hoag. Thanks to the support of Hoag Innovators, Hoag is leading the fight against glioblastoma (GBM)—the most aggressive form of brain cancer—through two groundbreaking clinical trials.
The Hoag Family Cancer Institute and Hoag’s Pickup Family Neurosciences Institute are leading the charge against glioblastoma (GBM), the most aggressive form of brain cancer, with two groundbreaking clinical trials, reflecting Hoag’s commitment to delivering the future of medicine to patients today.
One study is exploring how focused ultrasound (FUS) technology can temporarily open the blood-brain barrier, paving the way for advanced diagnostic tools and more effective treatments. Supported in part by a philanthropic investment from Hoag Innovators, this revolutionary technology is also being used to improve outcomes for patients with Parkinson’s disease, demonstrating its transformative potential in multiple areas of care.
In another trial, Hoag is one of only two sites worldwide testing a combination of immunotherapy treatments aimed at slowing GBM progression. These therapies have shown promise in treating other cancers and offer new hope to patients facing this challenging disease. Through the support of philanthropy and a collaborative, multidisciplinary approach, Hoag continues to lead the way in delivering tomorrow’s medicine today, providing cutting-edge care tailored to each patient’s unique needs.
Hoag’s “privademic” model combines the expertise and innovation of an academic institution with the personalized care of a private healthcare system, enabling swift adoption of cutting-edge treatments.
“Hoag's dedication to innovation has extended lives and improved the quality of life for the community,” said Robert G. Louis, MD, FAANS, Empower360 Endowed Chair in Skull Base and Minimally Invasive Neurosurgery, Chief of the Division of Neurosurgery and Director of the Pituitary & Skull Base and Pituitary Tumor Program in Hoag's Pickup Family Neurosciences Institute. “The use of focused ultrasound is just one of many examples of Hoag’s promise to our community to provide the treatment options of tomorrow to our patients today,” he said.
To dive deeper into Hoag’s leading-edge clinical trials, click here.
About Hoag Innovators
The LIBERATE study and Hoag’s acquisition of focused ultrasound technology were made possible through funding from Hoag Innovators. This dynamic group of philanthropists, entrepreneurs, and community leaders drives innovation at Hoag by supporting initiatives that advance patient care and treatment.
To learn more about Hoag Innovators and their impact, visit the website here.
Sign up for our Newsletter
